1. Market Research
  2. > Business Services
  3. > Research and Development Market Trends
  4. > CytoTools AG - Product Pipeline Review - 2015

CytoTools AG - Product Pipeline Review - 2015

  • August 2015
  • -
  • Global Markets Direct
  • -
  • 29 pages

CytoTools AG - Product Pipeline Review - 2015

Summary

Global Markets Direct’s, ‘CytoTools AG - Product Pipeline Review - 2015’, provides an overview of the CytoTools AG’s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of CytoTools AG’s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides brief overview of CytoTools AG including business description, key information and facts, and its locations and subsidiaries
- The report reviews current pipeline of CytoTools AG’s human therapeutic division and enlists all their major and minor projects
- The report features product description and descriptive mechanism of action for key pipeline products along with the product’s developmental history and major milestones
- Special feature on out-licensed and partnered product portfolio
- The report summarizes all the dormant and discontinued pipeline projects
- Latest company statement
- Latest news and deals relating to the CytoTools AG’s pipeline products

Reasons to buy

- Evaluate CytoTools AG’s strategic position with total access to detailed information on its product pipeline
- Assess the growth potential of CytoTools AG in its therapy areas of focus
- Identify new drug targets and therapeutic classes in the CytoTools AG’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
- Develop strategic initiatives by understanding the focus areas of CytoTools AG and exploit collaboration and partnership opportunities
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Plan mergers and acquisitions effectively by identifying the most promising pipeline of CytoTools AG
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Explore the dormant and discontinued projects of CytoTools AG and identify potential opportunities in those areas
- Avoid Intellectual Property Rights related issues

Table Of Contents

CytoTools AG - Product Pipeline Review - 2015
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
CytoTools AG Snapshot 5
CytoTools AG Overview 5
Key Information 5
Key Facts 5
CytoTools AG - Research and Development Overview 6
Key Therapeutic Areas 6
CytoTools AG - Pipeline Review 8
Pipeline Products by Stage of Development 8
Pipeline Products - Monotherapy 9
CytoTools AG - Pipeline Products Glance 10
CytoTools AG - Late Stage Pipeline Products 10
Pre-Registration Products/Combination Treatment Modalities 10
Phase III Products/Combination Treatment Modalities 11
CytoTools AG - Clinical Stage Pipeline Products 12
Phase II Products/Combination Treatment Modalities 12
Phase I Products/Combination Treatment Modalities 13
CytoTools AG - Early Stage Pipeline Products 14
Preclinical Products/Combination Treatment Modalities 14
Discovery Products/Combination Treatment Modalities 15
CytoTools AG - Drug Profiles 16
CL-05 16
Product Description 16
Mechanism of Action 16
RandD Progress 16
PEP-04 18
Product Description 18
Mechanism of Action 18
RandD Progress 18
HMW-02Ak 19
Product Description 19
Mechanism of Action 19
RandD Progress 19
HMW-02Ap 20
Product Description 20
Mechanism of Action 20
RandD Progress 20
LMW-0X 21
Product Description 21
Mechanism of Action 21
RandD Progress 21
CytoTools AG - Pipeline Analysis 22
CytoTools AG - Pipeline Products by Route of Administration 22
CytoTools AG - Pipeline Products by Molecule Type 23
CytoTools AG - Recent Pipeline Updates 24
CytoTools AG - Dormant Projects 26
CytoTools AG - Locations And Subsidiaries 27
Head Office 27
Other Locations and Subsidiaries 27
Appendix 28
Methodology 28
Coverage 28
Secondary Research 28
Primary Research 28
Expert Panel Validation 28
Contact Us 28
Disclaimer 29

List of Tables
CytoTools AG, Key Information 5
CytoTools AG, Key Facts 5
CytoTools AG - Pipeline by Indication, 2015 7
CytoTools AG - Pipeline by Stage of Development, 2015 8
CytoTools AG - Monotherapy Products in Pipeline, 2015 9
CytoTools AG - Pre-Registration, 2015 10
CytoTools AG - Phase III, 2015 11
CytoTools AG - Phase II, 2015 12
CytoTools AG - Phase I, 2015 13
CytoTools AG - Preclinical, 2015 14
CytoTools AG - Discovery, 2015 15
CytoTools AG - Pipeline by Route of Administration, 2015 22
CytoTools AG - Pipeline by Molecule Type, 2015 23
CytoTools AG - Recent Pipeline Updates, 2015 24
CytoTools AG - Dormant Developmental Projects,2015 26
CytoTools AG, Subsidiaries 27

List of Figures
CytoTools AG - Pipeline by Top 10 Indication, 2015 7
CytoTools AG - Pipeline by Stage of Development, 2015 8
CytoTools AG - Monotherapy Products in Pipeline, 2015 9
CytoTools AG - Pipeline by Top 10 Route of Administration, 2015 22
CytoTools AG - Pipeline by Top 10 Molecule Type, 2015 23

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
Integrin Alpha 7 (ITGA7) - Pipeline Review, H2 2016

Integrin Alpha 7 (ITGA7) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • August 2016
  • by Global Markets Direct

Integrin Alpha 7 (ITGA7) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘Integrin Alpha 7 (ITGA7) - Pipeline Review, H2 2016’, provides in depth analysis on Integrin Alpha 7 (ITGA7) ...

Pulmonary Fibrosis - Pipeline Review, H2 2016

Pulmonary Fibrosis - Pipeline Review, H2 2016

  • $ 2000
  • Company report
  • September 2016
  • by Global Markets Direct

Pulmonary Fibrosis - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘Pulmonary Fibrosis - Pipeline Review, H2 2016’, provides an overview of the Pulmonary Fibrosis pipeline landscape. ...

Cognitive Impairment - Pipeline Review, H2 2016

Cognitive Impairment - Pipeline Review, H2 2016

  • $ 2000
  • Company report
  • September 2016
  • by Global Markets Direct

Cognitive Impairment - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘Cognitive Impairment - Pipeline Review, H2 2016’, provides an overview of the Cognitive Impairment pipeline landscape. ...


ref:plp2015

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.